Table 5.
Novel HDACi combination therapies under investigation for relapsed/refractory peripheral T-cell lymphomas (Refer to Enrica Marchi et al.) [55]
| Combination trials | Mechanism of action | Phase | ClinicalTrial.gov ID |
|---|---|---|---|
| Chidamide + CHOP | Anthracycline-containing regimens | I | NCT02809573 |
| Chidamide + Cyclophosphamide + Thalidomide | HDAC inhibitor + Immunomodulatory drugs | II | NCT02879526 |
| Romidepsin + CHOEP | Anthracycline-containing regimens | I/II | NCT02223208 |
| Romidepsin + CHOP | Anthracycline-containing regimens | III | NCT01796002 |
| Romidepsin + ICE | Anthracycline-containing regimens | I | NCT01590732 |
| Romidepsin + Lenalidomide | HDAC inhibitor + Immunomodulatory drug |
II I/II |
NCT02232516 NCT01742793 |
| Belinostat + Carfilzomib | HDAC inhibitor + proteasome inhibitor | I | NCT02142530 |
| Pralatrexate + Romidepsin | HDAC inhibitor + antifolate | I/II | NCT01947140 |
| Romidepsin + 5-Azacitadine | hypomethylation agent + HDAC inhibitor | I/II | NCT01998035 |